[go: up one dir, main page]

MA26722A1 - Nouveaux composes et medicaments les contenant - Google Patents

Nouveaux composes et medicaments les contenant

Info

Publication number
MA26722A1
MA26722A1 MA25913A MA25913A MA26722A1 MA 26722 A1 MA26722 A1 MA 26722A1 MA 25913 A MA25913 A MA 25913A MA 25913 A MA25913 A MA 25913A MA 26722 A1 MA26722 A1 MA 26722A1
Authority
MA
Morocco
Prior art keywords
group
hydrogen atom
lower alkyl
alkyl
alcoxy
Prior art date
Application number
MA25913A
Other languages
English (en)
Inventor
Boes Michael
Galley Guido
Hoffmann Torsten
Hunkeler Walter
Stadler Heinz
Branca Quirico
Godel Thierry
Schnider Patrick
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26722A1 publication Critical patent/MA26722A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRÉSENTE INVENTION A TRAIT à DES COMPOSÉS DE FORMULE GÉNÉRALE : DANS LAQUELLE R EST UN ATOME D'HYDROGèNE, UN GROUPE ALKYLE INFÉRIEUR, ALCOXY INFÉRIEUR, UN ATOME D'HALOGèNE OU UN GROUPE TRIFLUOROMÉTYLE; R1 EST UN ATOME D'HYDROGèNE OU D'HALOGèNE; OU R ET R1 PEUVENT eTRE ENSEMBLE -CH=CH-CH=CH-; R2 ET R2' SONT INDÉPENDAMMENT L'UN DE L'AUTRE UN ATOME D'HYDROGèNE, D'ALOGèNE UN GROUPE TRIFLUOROMÉTYLE, UN GROUPE ALCOXY INFÉRIEUR OU CYANO; OU R2 ET R2' PEUVENT eTRE, PRIS ENSEMBLE, -CH= CH- CH= CH-,ÉVENTUELLEMENT SUBSTITUÉ (PAR UN OU PLUSIEURS SUBSTITUANTS CHOISIS PARMI LES GROUPES ALKYLE INFÉRIEUR OU ALCOXY INFÉRIEUR ; R3 EST UN ATOME D'HYDROGèNE , UN GROUPE ALKYLE INFÉRIEUR OU FORME UN GROUPE CYCLOALKYLE; R4 EST UN ATOME D'HYDROGèNE, -N(R5) 2', -N (R5) (CH2) NOH, - N(R5) S (O) 2 -(ALKYLE INFÉRIEUR) , -N(R5) S (O) 2 -PHÉNYLE, -N=CH- N(R5)2, -N(R5) C (O) R5 OU UNE AMINE TERTIAIRE CYCLIQUE DU GROUPE. R5 SONT INDÉPENDAMMENT LES UNS DES AUTRES, UN ATOME D'HYDROGèNE, UN GROUPE CYCLOALKYLE EN C3 à C6, BENZYLE OU ALKYLE INFÉRIEUR ; R6 EST UN ATOME D'HYDROGèNE, UN GROUPE HYDROXY, ALKYLE INFÉRIEUR, (CH2) NCOO- (ALKYLE INFERIEUR), -N(R5) CO- (ALKYLE INFÉRIEUR), HYDROXY (ALKYLE INFÉRIEUR) , CYANO, - (CH2) NO(CH2)NOH, -CHO OU UN GROUPE HÉTÉROCYCLIQUE à 5 OU 6 ÉLÉMENTS, ÉVENTUELLEMENT LIÉ PAR L'INTERMÉDIAIRE D'UN GROUPE ALKYLèNE, X EST -C(O) N 5R5) -, -(CH2)MO-, -(CH2) MN(R5) -, -N(R5) C(O) -, OU -N(R5) (CH2) M; N VAUT DE O à 4. ET M VAUT 1 OU 2 ET LEURS SELS D'ADDITION ACCEPTABLES SUR LE PLAN PHARMACEUTIQUE. LES COMPOSÉS DE FORMULE 1 REPRÉSENTENT UNE IFFINITÉ ÉLEVÉE ENVERS LE RECEPTEUR DE NK-1. ON PEUT LES UTILISER POUR LE TRAITEMENT DE MALADIES QUI SONT APPARENTÉS AUX ANTAGONISTES DU RECEPTEUR DE NK-1.
MA25913A 1999-02-24 2000-02-23 Nouveaux composes et medicaments les contenant MA26722A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99103504 1999-02-24
EP99123689 1999-11-29

Publications (1)

Publication Number Publication Date
MA26722A1 true MA26722A1 (fr) 2004-12-20

Family

ID=26152908

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25913A MA26722A1 (fr) 1999-02-24 2000-02-23 Nouveaux composes et medicaments les contenant

Country Status (54)

Country Link
US (2) US6297375B1 (fr)
EP (2) EP1035115B1 (fr)
JP (1) JP3399900B2 (fr)
KR (1) KR100384904B1 (fr)
CN (1) CN1142144C (fr)
AR (2) AR029614A1 (fr)
AT (2) ATE496032T1 (fr)
AU (1) AU767048B2 (fr)
BE (1) BE2015C057I2 (fr)
BG (1) BG64554B1 (fr)
BR (1) BRPI0000908B8 (fr)
CA (1) CA2299139C (fr)
CY (3) CY1111317T1 (fr)
CZ (1) CZ300596B6 (fr)
DE (3) DE60045564D1 (fr)
DK (2) DK1394150T3 (fr)
EA (1) EA003673B1 (fr)
EG (1) EG23817A (fr)
ES (3) ES2359235T3 (fr)
FR (2) FR2790473B1 (fr)
GB (1) GB2347422A (fr)
GE (1) GEP20022676B (fr)
GT (1) GT200000017A (fr)
HR (2) HRP20000097B1 (fr)
HU (1) HU227629B1 (fr)
IL (1) IL134654A (fr)
IS (1) IS2116B (fr)
IT (1) IT1320763B1 (fr)
JO (1) JO2294B1 (fr)
LT (1) LTC1035115I2 (fr)
LU (1) LU92745I2 (fr)
MA (1) MA26722A1 (fr)
ME (1) ME00593B (fr)
MY (2) MY123648A (fr)
NL (1) NL300758I2 (fr)
NO (1) NO315554B1 (fr)
NZ (1) NZ502948A (fr)
OA (1) OA11680A (fr)
PA (1) PA8491101A1 (fr)
PE (1) PE20001467A1 (fr)
PL (1) PL217311B1 (fr)
PT (2) PT1035115E (fr)
RS (3) RS20080562A (fr)
SE (1) SE1035115T5 (fr)
SG (1) SG91856A1 (fr)
SI (1) SI1035115T1 (fr)
SK (2) SK287912B6 (fr)
SV (1) SV2002000024A (fr)
TN (1) TNSN00032A1 (fr)
TR (1) TR200000520A3 (fr)
TW (1) TWI288746B (fr)
UA (1) UA71547C2 (fr)
UY (1) UY32314A (fr)
ZA (1) ZA200000894B (fr)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3979099A (en) * 1998-05-11 1999-11-29 Philadelphia Health & Education Corporation (mct-1), a human oncogene
RU2238264C2 (ru) * 1999-02-24 2004-10-20 Ф.Хоффманн-Ля Рош Аг Производные бензола или пиридина и фармацевтическая композиция на их основе
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
SI1103545T1 (en) * 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
JP3938651B2 (ja) * 2000-04-13 2007-06-27 セントラル硝子株式会社 光学活性α−メチル−ビス−３、５−（トリフルオロメチル）ベンジルアミンの製造方法
NZ523273A (en) * 2000-07-14 2004-08-27 F N-oxides as NK1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
ES2272408T3 (es) * 2000-12-14 2007-05-01 F. Hoffmann-La Roche Ag Matriz lipidica autoemulsificante (selm).
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
ATE366248T1 (de) 2001-03-27 2007-07-15 Eisai R&D Man Co Ltd N-aryl-substituiertes cyclisches aminderivat und medizin, die dieses als wirkstoff enthält
CA2444395C (fr) * 2001-04-23 2010-12-21 F. Hoffmann-La Roche Ag Utilisation d'antagonistes de recepteur de nk-1 contre l'hyperplasie benigne de la prostate
EP2266558B1 (fr) * 2001-06-07 2017-04-19 Analgesic Neuropharmaceuticals, LLC Traitement de la douleur neuropathique avec l'antagoniste du récepteur du N-méthyl-D-aspartate dextrométhorphan
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
MXPA04002220A (es) * 2001-09-10 2004-06-07 Hoffmann La Roche Formulaciones tixotropicas oleosas.
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
BR0314126A (pt) 2002-09-20 2005-06-28 Pfizer Prod Inc Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio
CA2508165C (fr) * 2002-12-06 2014-05-06 Purdue Research Foundation Pyridines destinees au traitement de tissus nerveux mammaliens leses
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
CA2514037C (fr) 2003-01-31 2012-03-13 F. Hoffmann-La Roche Ag Modification cristalline de 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-n-methyl-isobutyramide
DE602004008631T2 (de) * 2003-07-03 2008-07-10 F. Hoffmann-La Roche Ag Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
TWI280239B (en) * 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
TW201038270A (en) 2003-07-30 2010-11-01 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use in the inhibition of stearoyl-CoA desaturase
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 호프만-라 로슈 아게 Ｎｋ-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법
BRPI0418939A (pt) * 2004-07-06 2008-04-08 Xenon Pharmaceuticals Inc derivados de nicotinamida e sua utilização como agentes terapêuticos
CA2572645C (fr) * 2004-07-06 2011-01-18 F. Hoffmann-La Roche Ag Procede pour la preparation de derives pyridines carboxamide utilises comme intermediaires dans la synthese d'antagonistes de recepteurs nk-1
US20060030556A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency
WO2006013205A1 (fr) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Antagonistes des récepteurs de la neurokinine-1 pour le traitement des états sensibles à une élévation de la testostérone
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580855A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
CA2580857A1 (fr) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
US7569725B2 (en) * 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US20060135636A1 (en) * 2004-11-15 2006-06-22 Honeywell International Inc. Isocyanate-based polymer foams with nano-scale materials
CA2601935C (fr) * 2005-02-22 2013-04-09 F. Hoffmann-La Roche Ag Antagonistes de nk1
US7671065B2 (en) * 2005-02-24 2010-03-02 Janssen Pharmaceutica N.V. Pyridine derivatives as potassium ion channel openers
WO2006089674A2 (fr) 2005-02-25 2006-08-31 F.Hoffmann-La Roche Ag Comprimés présentant une dispersibilité de substance médicamenteuse améliorée
EP1863767B1 (fr) * 2005-03-23 2009-03-11 F. Hoffmann-Roche AG Metabolites pour les antagonistes nk-i contre le vomissement
EP2029138A1 (fr) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
EP1912983B1 (fr) * 2005-08-11 2011-06-08 Vertex Pharmaceuticals, Inc. Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
MY145713A (en) 2005-09-09 2012-03-30 Smithkline Beecham Corp Hexahydropyrazino [2,1-c][1,4]oxazin-8(1h)-yl pyridine derivatives and their use in the treatment of psychotic disorders
SI1928427T1 (sl) * 2005-09-23 2010-03-31 Hoffmann La Roche Nove formulacije za doziranje
KR101331768B1 (ko) * 2005-11-08 2013-11-22 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7872022B2 (en) 2006-04-03 2011-01-18 Hoffmann-La Roche Inc. Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
PL2674428T3 (pl) 2006-04-07 2017-01-31 Vertex Pharmaceuticals Incorporated Modulatory transporterów z kasetą wiążącą ATP
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CA2686838C (fr) 2007-05-09 2017-03-14 Vertex Pharmaceuticals Incorporated Modulateurs de cftr
DK2639223T3 (en) 2007-12-07 2017-06-19 Vertex Pharma Process for Preparation of Cycloalkylcarboxiamido-pyridine Benzoic Acids
HRP20170241T2 (hr) 2007-12-07 2023-03-17 Vertex Pharmaceuticals Incorporated Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
WO2009105498A1 (fr) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines utilisées comme inhibiteurs de fak
NZ736561A (en) 2008-02-28 2018-02-23 Vertex Pharma Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
BR112012003435A2 (pt) * 2009-08-27 2016-02-23 Glaxosmithkline Llc formas anidras de um derivado de píridina
LT2722045T (lt) 2009-11-18 2016-09-26 Helsinn Healthcare Sa Kompozicija skirta gydyti centralizuotai kontroliuojamą pykinimą ir vėmimą
EP2722045B1 (fr) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions pour traiter les nausées et vomissements à médiation centrale
TW201143768A (en) * 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RS54783B1 (sr) 2010-04-07 2016-10-31 Vertex Pharma Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline
DK3150198T3 (da) 2010-04-07 2021-11-01 Vertex Pharma Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
CA2797118C (fr) 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Procede de production de composes de cycloalkylcarboxamido-indole
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
EP2747560A4 (fr) * 2011-07-29 2015-02-25 Tempero Pharmaceuticals Inc Composés et méthodes
US20140155419A1 (en) * 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
JP2014530249A (ja) 2011-10-18 2014-11-17 ヘルシン ヘルスケア ソシエテ アノニム ネツピタントおよびパロノセトロンの治療学的組合せ
MX357328B (es) 2011-11-08 2018-07-05 Vertex Pharma Moduladores de trasportadores de casete enlazante de atp.
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
EP2872122A1 (fr) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques de (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide et son administration
ES2671418T3 (es) 2013-11-08 2018-06-06 Kissei Pharmaceutical Co., Ltd. Derivado de carboximetilpiperidina
RU2718044C2 (ru) 2013-11-12 2020-03-30 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
RS62140B1 (sr) 2014-04-15 2021-08-31 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
WO2015171489A1 (fr) * 2014-05-05 2015-11-12 Apicore Us Llc Procédés de fabrication de nétupitant et d'intermédiaires de celui-ci
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
HRP20211194T1 (hr) 2014-11-18 2021-10-29 Vertex Pharmaceuticals Inc. Postupak za provođenje testova velike propusnosti putem tekućinske kromatografije visoke djelotvornosti
CA3213864A1 (fr) 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Regime posologique de tradipitant
CN105061303A (zh) * 2015-08-03 2015-11-18 成都欣捷高新技术开发有限公司 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
JPWO2017099049A1 (ja) * 2015-12-07 2018-09-27 キッセイ薬品工業株式会社 Ｎｋ１受容体拮抗剤
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TW202246215A (zh) * 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
CN106892864A (zh) * 2015-12-21 2017-06-27 上海科胜药物研发有限公司 一种奈妥皮坦游离碱的晶型a及其制备方法
AU2016377658B2 (en) 2015-12-22 2022-09-29 Endosome Therapeutics, Inc. Tripartite modulators of endosomal G protein-coupled receptors
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
KR20250069704A (ko) 2017-06-30 2025-05-19 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
CN109384712B (zh) * 2017-08-14 2021-05-07 北京宽厚医药科技有限公司 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用
WO2019038656A1 (fr) 2017-08-21 2019-02-28 Leiutis Pharmaceuticals Pvt, Ltd Nouvelles formulations à triple combinaison pour une thérapie antiémétique
EP4450126A3 (fr) * 2018-09-28 2025-02-19 Vanda Pharmaceuticals Inc. Utilisation de tradipitant dans le mal des transports
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
US12351557B2 (en) 2018-12-24 2025-07-08 Eustralis Pharmaceuticals Limited Chemical compound manufacture, new salt form, and therapeutic uses thereof
CN112174881B (zh) * 2019-07-04 2022-06-21 上海森辉医药有限公司 一种奈妥匹坦的衍生物及其制备方法
WO2021035289A1 (fr) * 2019-08-23 2021-03-04 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Méthodes thérapeutiques et utilisations associées
AU2021246889A1 (en) 2020-04-03 2022-10-13 Nerre Therapeutics Limited An NK-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ARDS) or multiple organ dysfunction syndrome (MODS)
MX2022014901A (es) 2020-06-02 2023-01-18 Nerre Therapeutics Ltd Antagonistas del receptor de neuroquinina (nk)-1 para su uso en el tratamiento de condiciones de fibrosis pulmonar promovidas por lesion mecanica a los pulmones.
US12097197B2 (en) 2021-12-21 2024-09-24 Slayback Pharma Llc Stable liquid compositions of netupitant and palonosetron
EP4385497A1 (fr) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Combinaison de doses fixes sans antioxydant de nétupitant et de palonosétron
EP4633608A1 (fr) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Association de dose fixe sans antioxydant de netupitant et de palonosétron
IL321446A (en) 2022-12-12 2025-08-01 Tiefenbacher Alfred E Gmbh & Co Kg Fixed-dose combination including netopitant and flunosterone
EP4385500A1 (fr) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Combinaison de doses fixes comprenant du nétupitant et du palonosétron

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1557420A (en) 1977-03-10 1979-12-12 Soc D Etudes Prod Chimique Preparation of isobutyramide derivatives
KR810001320B1 (ko) 1977-03-17 1981-10-14 삐에르 위브 신규한 이소부티라미드류의 제조방법
KR810001697B1 (ko) 1978-02-06 1981-10-27 삐에르 위브 이소부티라미드 유도체의 신규한 제조방법
DE3366369D1 (en) 1982-03-17 1986-10-30 Smith Kline French Lab Pyridine derivatives
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
GB8607313D0 (en) 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
CA1339423C (fr) 1988-09-14 1997-09-02 Yuji Ono Pyridines et leur emploi en pharmacie
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
US4973597A (en) 1989-06-30 1990-11-27 Eli Lilly And Company Anticonvulsant agents
HU207047B (en) 1989-11-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
US5364943A (en) 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
GB9021056D0 (en) 1990-09-27 1990-11-07 Pfizer Ltd Antiarrhythmic agents
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
WO1994003429A1 (fr) 1992-07-31 1994-02-17 Merck Sharp & Dohme Limited Amines substituees utiles comme antagonistes du recepteur de la tachykinine
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
GB9305672D0 (en) 1993-03-19 1993-05-05 Wyeth John & Brother Ltd Amide derivatives
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
NZ277839A (en) 1993-12-29 1998-01-26 Merck Sharp & Dohme Substituted morpholine derivatives, preparation and pharmaceutical compositions thereof
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
CA2187531A1 (fr) 1994-06-06 1995-12-14 David Christopher Horwell Antagonistes du recepteur de la tachykinine (nk1)
US6294537B1 (en) 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
NO309272B1 (no) * 1995-03-24 2001-01-08 Takeda Chemical Industries Ltd Cykliske forbindelser, preparater inneholdende forbindelsene samt mellomprodukter for fremstilling av forbindelsene
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
DE69728138T2 (de) 1996-03-29 2004-09-16 Pfizer Inc. 6-phenylpyridinderivate
WO1998021185A1 (fr) 1996-11-08 1998-05-22 Sankyo Company, Limited Arylurees ou derives d'arylmethylcarbamyle
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
RU2238264C2 (ru) * 1999-02-24 2004-10-20 Ф.Хоффманн-Ля Рош Аг Производные бензола или пиридина и фармацевтическая композиция на их основе
SI1103545T1 (en) * 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives

Also Published As

Publication number Publication date
EA003673B1 (ru) 2003-08-28
NL300758I1 (fr) 2015-12-22
FR15C0049I2 (fr) 2016-02-12
EP1394150B1 (fr) 2011-01-19
US20020091265A1 (en) 2002-07-11
HK1031223A1 (en) 2001-06-08
SI1035115T1 (en) 2005-02-28
HU227629B1 (en) 2011-10-28
TR200000520A2 (tr) 2001-06-21
EP1394150A1 (fr) 2004-03-03
CY1111317T1 (el) 2015-08-05
US6297375B1 (en) 2001-10-02
ES2171109A1 (es) 2002-08-16
GB0003908D0 (en) 2000-04-05
CY2015041I2 (el) 2016-06-22
SK287911B6 (sk) 2012-03-02
EA200000155A3 (ru) 2000-12-25
UA71547C2 (uk) 2004-12-15
EP1035115B1 (fr) 2004-09-29
JO2294B1 (en) 2005-09-12
PT1394150E (pt) 2011-02-17
ITMI20000328A1 (it) 2001-08-23
LU92745I2 (fr) 2015-08-17
BE2015C057I2 (fr) 2019-03-06
BG104187A (en) 2000-11-30
ES2359235T3 (es) 2011-05-19
FR15C0049I1 (fr) 2015-08-28
FR2790473A1 (fr) 2000-09-08
FR2790473B1 (fr) 2004-04-02
AU767048B2 (en) 2003-10-30
SE1035115T3 (sv) 2005-01-18
IL134654A (en) 2011-03-31
EP1035115A1 (fr) 2000-09-13
ME00593B (me) 2015-08-31
GEP20022676B (en) 2002-04-25
MEP5709A (en) 2011-12-20
SK287912B6 (sk) 2012-03-02
PL338598A1 (en) 2000-08-28
JP3399900B2 (ja) 2003-04-21
RS20080562A (sr) 2009-09-08
CY2015042I1 (el) 2016-06-22
IS5381A (is) 2000-08-25
YU9500A (sh) 2002-11-15
PA8491101A1 (es) 2001-04-30
ZA200000894B (en) 2000-08-24
RS50194B (sr) 2009-05-06
DK1394150T3 (da) 2011-03-21
TWI288746B (en) 2007-10-21
IS2116B (is) 2006-06-15
IT1320763B1 (it) 2003-12-10
CZ2000609A3 (cs) 2001-01-17
NL300758I2 (fr) 2015-12-22
NO20000885D0 (no) 2000-02-23
LTC1035115I2 (lt) 2017-04-10
BRPI0000908B8 (pt) 2021-05-25
AU1946800A (en) 2000-08-31
IL134654A0 (en) 2001-04-30
CZ300596B6 (cs) 2009-06-24
PE20001467A1 (es) 2000-12-20
TR200000520A3 (tr) 2001-06-21
NO315554B1 (no) 2003-09-22
DE60045564D1 (de) 2011-03-03
NZ502948A (en) 2001-09-28
ITMI20000328A0 (it) 2000-02-23
MY123648A (en) 2006-05-31
KR100384904B1 (ko) 2003-05-22
SE1035115T5 (sv) 2015-08-04
PT1035115E (pt) 2005-01-31
SV2002000024A (es) 2002-01-23
CA2299139A1 (fr) 2000-08-24
LTPA2015036I1 (lt) 2015-11-25
RS53869B1 (sr) 2015-08-31
PL217311B1 (pl) 2014-07-31
HRP20000097A2 (en) 2001-10-31
HRP20080306B1 (hr) 2015-01-30
CN1270959A (zh) 2000-10-25
GB2347422A (en) 2000-09-06
ATE277905T1 (de) 2004-10-15
AR029614A1 (es) 2003-07-10
JP2000247957A (ja) 2000-09-12
HRP20000097B1 (en) 2008-12-31
ES2226622T3 (es) 2005-04-01
US6479483B2 (en) 2002-11-12
EA200000155A2 (ru) 2000-08-28
BG64554B1 (bg) 2005-07-29
HRP20080306A2 (en) 2008-11-30
NO20000885L (no) 2000-08-25
GT200000017A (es) 2001-08-15
BR0000908A (pt) 2000-09-12
MY147451A (en) 2012-12-14
ES2171109B2 (es) 2003-09-16
OA11680A (fr) 2005-01-12
TNSN00032A1 (fr) 2005-11-10
DE10008042A1 (de) 2000-08-31
SG91856A1 (en) 2002-10-15
CY2015041I1 (el) 2016-06-22
HUP0000748A3 (en) 2003-12-29
DE60014216T2 (de) 2006-03-02
SK2352000A3 (en) 2000-09-12
UY32314A (es) 2010-02-26
CN1142144C (zh) 2004-03-17
HUP0000748A2 (en) 2001-03-28
DK1035115T3 (da) 2005-01-24
CA2299139C (fr) 2011-03-29
DE60014216D1 (de) 2004-11-04
AR062949A2 (es) 2008-12-17
BR0000908B1 (pt) 2013-09-24
ATE496032T1 (de) 2011-02-15
EG23817A (en) 2007-09-19
HU0000748D0 (en) 2000-04-28
KR20000062599A (ko) 2000-10-25

Similar Documents

Publication Publication Date Title
MA26722A1 (fr) Nouveaux composes et medicaments les contenant
RU2167152C2 (ru) N-замещенные азагетероциклические карбоновые кислоты или их фармацевтически приемлемые соли, способ их получения, фармацевтическая композиция на их основе и способ ингибирования нейрогенного воспаления
JP3038155B2 (ja) 神経保護剤を用いる耳鳴治療
JP5746860B2 (ja) ヒストンデアセチラーゼ阻害剤
US6426347B2 (en) 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands
JP3176935B2 (ja) ドーパミンリセプタサプタイプ特異性リガンドとしてのｎ―アミノアルキルジベンゾフランカルボキサミド
JP2000504677A (ja) ５ｈｔ７レセプター・アンタゴニスト用のスルホンアミド誘導体
US6429312B2 (en) N-aminoalkyldibenzothiopencarboxamide receptor subtype specific ligands
MA28111A1 (fr) Derives des
US4381398A (en) Amino-alcohol derivatives
GB2243832A (en) 2-substituted 4-acetamido-5-chloro-n-[2-(diethylamino)ethyl]-benzamide derivative
AU593247B2 (en) Oxothiazolidine compounds
CA2251989A1 (fr) Aminoalkylcarboxamides tricycliques, nouveaux ligands specifiques a des sous-types de recepteurs de la dopamine d3
EP0306827A1 (fr) Amides, procédé pour leur préparation et composition pour l'activation des fonctions gastromotrices
MA26752A1 (fr) Composes de quinoleine, leurs preparations et leurs utilisations therapeutiques.
HUP0100781A2 (hu) A jóindulatú prosztata hiperplázia kezelésére alkalmas szubsztituált piridino aril piperazin-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
DE60130628D1 (de) Aminophenoxyacetamid derivate und diese enthaltende pharmazeutische zusammensetzungen
JP3041834B2 (ja) Ｎ―アミノアルキル―２―アントラキノンカルボキサミド；ドーパミンレセプターサブタイプに特異的な新しい配位子
US4880821A (en) α-nitroalkylnitrobenzenesulfonamides
MA27492A1 (fr) Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
BE905018A (fr) Nouveaux benzamides, leur procede de preparation et leur application dans le domaine therapeutique.
JPH06234753A (ja) イソオキサゾール化合物およびその塩
JPH037229A (ja) 脳神経機能改善剤
BE1000730A5 (fr) Nouvelles tetrahydrocarbazolones, composition pharmaceutique les contenant et leur procede de preparation.
KR100307845B1 (ko) 신규한n-아미노알킬-1-비페닐렌일-2-카르복스아미드신규한도파민수용체서브타입특이적리간드